Recombinant Human ULBP-1 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human ULBP-1 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind rhNKG2D/Fc Chimera in a functional ELISA.
• Source: Spodoptera frugiperda, Sf 21 (stably transfected)-derived human ULBP-1 protein
  

  Human ULBP-1 (Gly26 - Pro215) Accession # Q9BZM6	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: Q9BZM6
• N-terminal Sequence: Gly26
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: ULBP1
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 48.8 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ULBP-1 Fc Chimera Protein, CF

• ALCAN-beta
• MULT-1
• N2DL1
• N2DL-1
• NKG2D ligand 1
• NKG2DL
• NKG2DL1
• RAET1I
• RAET1Ialcan-beta
• Retinoic acid early transcript 1I
• UL16 binding protein 1
• UL16-binding protein 1
• ULBP1
• ULBP-1

Background

ULBP-1 is a member of a family of cell-surface proteins that function as ligands for human NKG2D. ULBP-1 has also been described under the names RaeT1I (retinoic acid early transcript), ALCAN-beta, and NKG2DL1. The name ULBP-1 derives from the original identification of three proteins, ULBP-1, -2, and -3, as ligands for the human cytomegalovirus glycoprotein UL16; they were designated UL16 binding proteins (ULBP). The gene for ULBP-1 resides in a cluster of ten related genes, six of which encode potentially functional glycoproteins. Amino acid sequence identity within this family ranges from 30 - 95%. These proteins are distantly related to MHC class I proteins, but they possess only the alpha 1 and alpha 2 Ig-like domains, and they have no capacity to bind peptide or interact with beta 2-microglobulin. They are anchored to the membrane via a GPI-linkage. ULBP-1 and several other family members are known to bind to human NKG2D, an activating receptor expressed on NK cells, NKT cells, gamma δ T cells, and CD8⁺ alpha beta T cells. Engagement of NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. ULBP-1 is expressed on some tumor cells and has been implicated in tumor surveillance (1 - 8).

1. Cosman, D. et al. (2001) Immunity 14:123.
2. Kubin, M. et al. (2001) Eur. J. Immunol. 31:1428.
3. Sutherland, C. et al. (2002) J. Immunol. 168:671.
4. Steinle, A. et al. (2001) Immunogenetics 53:279.
5. Sutherland, C. et al. (2001) Immunol. Rev. 181:185
6. Pende, D. et al. (2002) Cancer Res. 62:6178.
7. Radosavljevic, M. et al. (2002) Genomics 79:114
8. NKG2D and its Ligands, 2002, www.RnDSystems.com.

Publications for ULBP-1 (1380-UL)(7)

Publications using 1380-UL

• Seller, A;Tegeler, CM;Mauermann, J;Schreiber, T;Hagelstein, I;Liebel, K;Koch, A;Heitmann, JS;Greiner, SM;Hayn, C;Dannehl, D;Engler, T;Hartkopf, AD;Hahn, M;Brucker, SY;Salih, HR;Märklin, M; Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome International journal of molecular sciences 2024-04-08 [PMID: 38612935] (ELISA Standard, Human)
• S Weil, S Memmer, A Lechner, V Huppert, A Giannattas, T Becker, A Müller-Run, K Lampe, D Beutner, A Quaas, R Schubert, E Herrmann, A Steinle, U Koehl, L Walter, MS von Bergwe, J Koch Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma Front Immunol, 2017-04-10;8(0):387. 2017-04-10 [PMID: 28443091] (Bioassay)
• AB Raneros, AM Puras, RM Rodriguez, E Colado, T Bernal, E Anguita, AV Mogorron, AC Gil, JR Vidal-Cast, L Márquez-Ki, PD Bulnes, AM Marin, MCG Garay, B Suarez-Alv, C Lopez-Larr Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition Oncotarget, 2017-05-09;8(19):31959-31976. 2017-05-09 [PMID: 28404876] (ELISA (Standard), Human)
• Ibusuki A, Kawai K, Yoshida S, Uchida Y, Nitahara-Takeuchi A, Kuroki K, Kajikawa M, Ose T, Maenaka K, Kasahara M, Kanekura T NKG2D triggers cytotoxicity in murine epidermal gammadelta T cells via PI3K-dependent, Syk/ZAP70-independent signaling pathway. J Invest Dermatol, 2013-08-20;134(2):396-404. 2013-08-20 [PMID: 23962808] (Bioassay, Mouse)
• Nuckel H, Switala M, Sellmann L, Horn PA, Durig J, Duhrsen U, Kuppers R, Grosse-Wilde H, Rebmann V The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia, 2010-04-29;24(6):1152-9. 2010-04-29 [PMID: 20428196] (ELISA (Standard))
• Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH, Ritz J, Canning C, Kutok J, Mihm MC, Dranoff G, Soiffer R Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc. Natl. Acad. Sci. U.S.A., 2009-08-26;106(37):15825-30. 2009-08-26 [PMID: 19717467] (ELISA (Capture), Human)
• Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U, Hofsteenge J, Gratwohl A, Tichelli A, Paluszewska M, Wiktor-Jedrzejczak W, Kalberer CP, Wodnar-Filipowicz A NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood, 2007-11-09;111(3):1428-36. 2007-11-09 [PMID: 17993609] (ELISA (Standard), Western Blot)

Bioinformatics

• Gene Symbol: ULBP1
• Uniprot:
  • Q9BZM6(Human)